6 August 2015 - BTG plc, the specialist healthcare company, today announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.

An estimated 3.7 million Canadians have varicose veins, with women twice as likely as men to develop varicosities.

Louise Makin, CEO of BTG plc, said: “We are pleased to receive approval in Canada for Varithena and look forward to the commercial launch during the first half of 2016. The controlled launch continues in the US reimbursed sector, where we consistently receive excellent feedback from physicians in relation to clinical performance and patient acceptability. We are also progressing development of related products for other venous disorders.”

For more details, go to: https://www.btgplc.com/media/press-releases/health-canada-approves-varithena/